Search
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Bremelanotide
go.drugbank.com/drugs/DB11653Approved[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [A179686] The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown.
Hyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigational[A199026] Hyaluronidase has been used in surgical settings for at least the past 60 years to improve the diffusion of local anesthetics. … Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigational[L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus. … In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection.
Thrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic … The cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents.
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Overall, 21 patients achieved insulin independence for a year or more, with 11 patients not needing insulin for 1 to 5 years and 10 patients for more than 5 years. … , by not relying on exogenous and intentional insulin administration to control blood glucose.
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). … [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.
Categories: Agents to Treat Airway Disease, Drugs for Obstructive Airway DiseasesCarisoprodol
go.drugbank.com/drugs/DB00395Approvedfor abuse in addition to a low risk of dependence [L5074]. … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnIt is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.
Mixtures: TL-Care DHAIsatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigational[L12099] Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. … granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.